2. 您的位置
3. 首页
4. 会议论文
5. Determining the prevalence of EGFR mutations in patients with advanced non-small-cell lung cancer (a

Determining the prevalence of EGFR mutations in patients with advanced non-small-cell lung cancer (a

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户：sadddddd

【摘 要】

：

Objective: IGNITE (a large, multinational, diagnostic, non-comparative, interventional study;NCT01788163) assessed EGFR mutation frequency in patients with advanced NSCLC of adenocarcinoma (ADC)/non-A

【作 者】

：

Chunlei Shi Meng-zhao Wang Yong He Yi-ping Zhang Sergei Tjulandin Marianne Ratcliffe Rose Mccormack Baohui Han 

【机 构】

：

Department of Respiratory Medicine, Shanghai Chest Hospital, Jiao Tong University,Shanghai, China

【出 处】

：

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会

【发表日期】

：

2015年4期

【关键词】

：

non-small-cell lung cancer 

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Objective: IGNITE (a large, multinational, diagnostic, non-comparative, interventional study;NCT01788163) assessed EGFR mutation frequency in patients with advanced NSCLC of adenocarcinoma (ADC)/non-ADC histology in Chinese patients.

其他文献

Efficacy and safety of nitroglycerin combined with chemotherapy in the elderly patients with advance

Objective: To investigate the efficacy and safety of the treatment of nitroglycerin combined with docetaxel/carboplatin chemotherapy for the elderly patients with advanced non-small cell lung cancer (

会议

Geriatric OncologyNSCLCNitroglycerin

消癌平注射液改善非小细胞肺癌细胞对gefitinib和erlotinib双重耐药的作用及机理

目的：通过吉非替尼(gefitinib)和厄洛替尼(erlotinib)双重耐药非小细胞肺癌(NSCLC)细胞HCC827/ER研究消癌平注射液(XAP)改善gefitinib和erlotinib耐药的作用及机理。方法：通过erlotinib 长期诱导形成耐药细胞株HCC827/ER,MTT检测细胞增殖,Taqman探针实时荧光定量PCR检测Met基因拷贝数,Western blot法检测细胞蛋白

会议

非小细胞肺癌消癌平注射液gefitinib和erlotinib双重耐药

Identifying the Role of Protein kinase CK2 in the Radiosensitivity of Non-small Cell Lung Cancer

Objective: Proteinkinase CK2 (also known ascasein kinase) is a highlyconserved seine/threonine protein kinase, which is ubiquitously expressed inmammalian cells.CK2 has been implicated in multiple phy

会议

Protein kinase CK2RadiosensitivityNon small cell

Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma

Objective: Stem-like cells in solid tumors are purported to contribute to cancer development and poor treatment outcome.The abilities to self-renew, differentiate, and resist anticancer therapies are

会议

lung cancerstem cellvitamin D

Consolidation Chemotherapy may Improve Survival for Patients with Locally Advanced Non-small-cell Lu

Objective: For patients with locally advanced non-small-cell lung cancer (LA-NSCLC), the role of consolidation chemotherapy (CCT) following concurrent chemoradiotherapy (CRT) is partially defined.

会议

Locally advanced non-small-cell lung cancerConsol

CACNA2D1 Is a Novel Biomarker for Tumor Initiating Cells and Has Therapeutic Effect in Non-Small Cel

Objective: Tumor initiating cells (TICs) are a small subpopulation within cancer that is thought to be resistant to conventional therapiesand capable of reinitiating tumors.

会议

Tumor initiating cellsnon small lung cancertarg

Progression of central nervous system metastases in advanced non-small cell lung cancer effectively

Objective: Central nervous system (CNS) progression is frequently detected in patients with favorable initial responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs), but

会议

Non-small cell lung cancergefitinbcentral nervous

Genome-wide screen of DNA methylation changes reveals GABBR2 as a novel potential treatment target f

Objective: Lung cancer is the leading cause of cancer related death in the world.The last decade has witnessed the rapid development of epidermal growth factor receptor (EGFR) directed targeted therap

会议

lung adenocarcinomaepidermal growth factor receptor (EGFR)tyrosine kinase inhi

PD-L1 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small C

Objective: Although neoadjuvant chemotherapy (NAC) for advanced lung cancer can improve operability and local disease control, the duration of benefit is limited before resistance develops.

会议

PD L1chemoresistanceneoadjuvant therapy

Pooled analysis of CNS response to alectinib in two phase 2studies of pre-treated ALK+ NSCLC

Objective: The central nervous system (CNS) is a frequent site of progression in ALK+ NSCLC patients treated with crizotinib, thus good CNS efficacy is of crucial importance for new ALK inhibitors.

会议

alectinibCNS metastasisALK positive non small cell